

Navin Kumar Chintala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9206202/publications.pdf>

Version: 2024-02-01

20
papers

1,227
citations

933447

10
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

1915
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. <i>Cancer Cell</i> , 2019, 36, 471-482.	16.8	280
2	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	9.4	222
3	Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche. <i>Cancer Research</i> , 2014, 74, 3454-3465.	0.9	151
4	Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs. <i>Journal of Immunology</i> , 2015, 194, 5529-5538.	0.8	131
5	Driving CARs on the uneven road of antigen heterogeneity in solid tumors. <i>Current Opinion in Immunology</i> , 2018, 51, 103-110.	5.5	88
6	Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2511.	1.6	75
7	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 16-26.	1.1	72
8	The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1. <i>Journal of Immunology</i> , 2017, 198, 2989-2999.	0.8	63
9	Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. <i>Nature Protocols</i> , 2021, 16, 1331-1342.	12.0	48
10	Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. , 2019, , .		38
11	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. <i>Lung Cancer</i> , 2021, 157, 48-59.	2.0	16
12	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 89-102.	1.1	16
13	Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1042.	2.8	10
14	Novel immunotherapy clinical trials in malignant pleural mesothelioma. <i>Annals of Translational Medicine</i> , 2017, 5, 245-245.	1.7	6
15	Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	4
16	MA11.01 Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion. <i>Journal of Thoracic Oncology</i> , 2018, 13, S392.	1.1	4
17	MA06.06 An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents' Anti-Tumor Efficacy. <i>Journal of Thoracic Oncology</i> , 2018, 13, S376.	1.1	3
18	Immunotherapy for thoracic malignancies. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 54-64.	0.6	0

#	ARTICLE	IF	CITATIONS
19	MA12.07 gC1qR Expression is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, S398.	1.1	0
20	MA05.03 Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, S371.	1.1	0